EpiCast Report: Migraine – Epidemiology Forecast to 2026

2017-08-10
Price :
Published : Aug-2017
No. of Pages : 30

EpiCast Report: Migraine – Epidemiology Forecast to 2026

Summary

Migraine is typically characterized by recurring headaches and throbbing pain on one side of the head accompanied by nausea, vomiting, or increased sensitivity to light or smell (Bigal and Lipton, 2006). While most migraineurs experience episodic migraines (EM), a small percentage suffers from chronic migraine (CM). Migraines are also classified into migraine with aura (MWA), in which the migraine is accompanied by other sensory symptoms, and migraine without aura (MOA).

In 2016, there were 73,914,635 total prevalent cases of migraine in adults ages 18 years and older in the 7MM. The US had the most cases, with 30,233,942, making up 40.90% of cases in the 7MM. Italy had the second most cases, with 12,231,868 cases, or 16.55% of cases in the 7MM. Spain had the fewest cases, with 2,199,892 cases (2.98% of cases in the 7MM). Italy also had the highest prevalence of migraine, with 23.63% of adult’s ages 18 years and older experiencing migraine in 2016. Spain had the lowest prevalence, at 5.54%.

In the 7MM, the number of total prevalent cases of migraine is expected to grow to 74,543,569 by 2026, at an Annual Growth Rate (AGR) of 0.09%. The US, France, Spain, and the UK are expected to see small increases in the number of total prevalent migraine cases, while Germany, Italy, and Japan are expected to see small decreases. The largest changes are expected in the US (AGR 0.60%) and Japan (AGR negative 0.87%). Since age- and sex-specific prevalence was held constant throughout the forecast period, all changes in the total prevalent cases of migraine are the result of demographic changes.

Our epidemiologists estimate that 1.61% of total migraine cases in the 7MM in 2016 were CM, corresponding to 1,189,614 cases. Due to the lack of country-specific sources, this percentage was applied to all markets.

The report “EpiCast Report: Migraine – Epidemiology Forecast to 2026” provides an overview of the risk factors, comorbidities, and the global and historical trends for migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases (diagnosed and undiagnosed) of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into EM and CM.

Scope

– The Migraine EpiCast Report provides an overview of the risk factors and global trends of migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into episodic migraine (EM) and chronic migraine (CM).
– The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Migraine EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global migraine market.
– Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for migraine therapeutics in each of the markets covered.
– Identify the percentage of migraine prevalent cases by frequency.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.” The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide. Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials “The Enterprise RBM Software segment to hold the largest market share in 2020.” Based on type, the RBM software market is segmented into Enterprise RB......
$5650

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

“The veterinary vaccines market is projected to grow at a CAGR of 7.2% during the forecast period (2020–2025).” The global veterinary vaccines market size is projected to reach USD 11.3 billion by 2025 from USD 8.0 billion in 2020, at a CAGR of 7.2%. The growth of this market is driven majorly by factors such as the initiatives by various government agencies and animal associations to maintain animal health, rising incidence of zoonotic diseases, growth in the companion animal population, and the rising demand for animal-derived food products are driving the growth of this market. On the other hand, the high storage cost of vaccines is restraining market growth. “By technology, the recombinant vaccines segment is expected to grow at the highest CAGR during the forecast period......
$4950

COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period." The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development. "The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period." The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs......
$5650

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

Social Media: Coronavirus Disease (COVID-19) Sector Impact

Social Media: Coronavirus Disease (COVID-19) Sector Impact Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. Scope - This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussi......
$995

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report Summary This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments. Scope This report is required reading for - - Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months - Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies. - Large ph......
$695

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Poland

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Poland Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Poland". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the Poland. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the Poland. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house ......
$1995

Coronavirus Disease (COVID-19) : Epidemiology Analysis and Forecast – Apr 2020

Coronavirus Disease (COVID-19): Epidemiology Analysis and Forecast - Apr 2020 Summary First reported in Wuhan, China, in December 2019, now more than 846,200 confirmed cases of COVID-19 are spread across 187 countries worldwide. The US is now the most heavily affected country worldwide. Forecasts expect new cases to decrease for most countries in the top markets reporting cases except for Russia, which has not yet reached peak. People at risk for severe COVID-19 include population with underlying health problems, such as respiratory disease, cardiovascular disease, cancer, diabetes, some rare diseases, and diabetes. New analysis available this month for severely obese populations likely to be at risk for sever COVID-19. The global CFR has increased to more than 7%. The age groups most......
$1995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Singapore

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analys......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy